drugset / Trial / NCT03335241
Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and toxicity of fludarabine with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum resistant or refractory ovarian cancer.
Timeline
- Start
- 2017-03-01
- Primary completion
- 2021-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Comparator | Pegylated liposomal doxorubicin | Unknown | 30 mg/m2 | Intravenous |
| Comparator | Pegylated liposomal doxorubicin | Unknown | 50 mg/m2 | Intravenous |